Arkady Yatskevich, OD
Optometrist · Dover, DENPI 1215027917
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,296 of the $1,519 with a category attached, or 85.3%. It is spread thinly across 16 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $771, 3.4 times the $230 reported in 2019.
Across 43 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$353
- Alcon$340
- Coopervision Inc.$241
- Sun Pharmaceutical Industries Inc.$142
- Biotissue Holdings Inc.$110
- Harrow Eye, LLC$84
- plus $248 from 10 others
What the payments were for
- Speaking & faculty fees$20413%
- Food & beverage$1,29685%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 5 | $353 |
| Alcon | 13 | $340 |
| Coopervision Inc. | 3 | $241 |
| Sun Pharmaceutical Industries Inc. | 6 | $142 |
| Biotissue Holdings Inc. | 1 | $110 |
| Harrow Eye, LLC | 3 | $84 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $40 |
| Thea Pharma Inc. | 2 | $35 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| Oyster Point Pharma, Inc. | 2 | $31 |
| Dompe US, Inc. | 1 | $30 |
| Novartis | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $12 |
| Maculogix, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MiSight Contact Lens$204
- MIEBO$125
- XIIDRA$125
- VYZULTA$125
- TOTAL30$120
How this compares
$1,519 in reported general payments places this provider in the 70th percentile of 146 optometrist providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 42 | $66,183 |
| XiidraLifitegrast | 24 | $38,182 |
| LumiganBimatoprost | 14 | $9,995 |
| MieboPerfluorohexyloctane/Pf | 11 | $7,935 |
| Travoprost | 31 | $6,243 |
| Timolol Maleate | 93 | $6,089 |
| Loteprednol Etabonate | 34 | $5,924 |
| Brimonidine Tartrate | 74 | $5,023 |
| Latanoprost | 196 | $4,944 |
| Difluprednate | 12 | $2,398 |
| Bimatoprost | 15 | $2,072 |
| Dorzolamide Hcl | 64 | $1,551 |
| Prednisolone Acetate | 21 | $1,122 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 53 | $977 |
| Ketorolac Tromethamine | 16 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $12 | $76,17856 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $353 | $46,11735 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $40 | $5,92434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 146 optometrist providers in Delaware.
Other optometrist in Dover
- Tiffany NguyenDover$3K
- Philip GrossDover$2K
- Laura CastilloDover$2K
- Samuel HalpernDover$2K
- Sheila MayaniDover$2K
- Colleen EverettDover$1K
- Adriane HohmannDover$1K
- Bethany LewallenDover$1K
- Robert WagonerDover$934
- Jennifer TuranoWilmington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.